Pharmaceuticals Industry Trends Spain - 2022

市場監測

  • 西班牙
  • 化學/制藥

2022年03月15日

Good growth prospects, but also constraints due to lower public healthcare spend

IT Spain pharma credit risk 2022

In Spain, demand for pharmaceuticals will continue to grow in 2022, in particular for vaccinations. At the same time, non-Covid related medical treatments and spending on drugs have rebounded since 2021, and will increase further this year.

In 2021, profit margins of Spanish pharmaceuticals producers increased. Those of wholesalers and distributors remained stable, but were also thin. Smaller pharmacies (usually run by self-employed business owners) recorded a slight decrease. We expect that profit margins will remain stable across all segments in 2022.

IT Spain pharma output 2022

As in many other European countries, the ageing Spanish population will support growth of pharmaceuticals demand in the mid- and long-term, in particular for special products. However, in the short-term high public debt will have an adverse impact on government spending, also putting constraints on expenditures made by the national health system. Public health authorities are known as tough negotiators with the pharmaceuticals industry, trying to reach large and comprehensive agreements in order to reduce total costs.

Most pharmaceutical wholesalers are concentrated in large cooperatives, and mainly financed by their own cooperative partners (pharmacies), while producers and laboratories are more dependent on bank loans. The average payment duration of 75 days is shorter than in most other Spanish industries. The payment behaviour is generally good, due to the sector´s low dependence on the economic cycle, a high export share and good access to external financing. We expect the number of payment delays and insolvencies to remain low in 2022.

Due to that, and the financial strength of most businesses, our underwriting stance is open across all segments. However, there are potential challenges ahead that need to be monitored, in particular any supply chain constraints in the future. As revenues of pharmaceutical businesses are highly dependent on public health budgets, we closely monitor related political developments and regulatory changes in the health system.

 

 

 

相關資料

免責聲明

Each publication available on or from our websites, such as, but not limited to webpages, reports, articles, publications, tips and helpful content, trading briefs, infographics, videos (each a “Publication”) is provided for information purposes only and is not intended as a recommendation or advice as to particular transactions, investments or strategies in any way to any reader. Readers must make their own independent decisions, commercial or otherwise, regarding the information provided. While we have made every attempt to ensure that the information contained in any Publication has been obtained from reliable sources, Atradius is not responsible for any errors or omissions, or for the results obtained from the use of this information. All information in any Publication is provided ’as is’, with no guarantee of completeness, accuracy, timeliness or of the results obtained from its use, and without warranty of any kind, express or implied. In no event will Atradius, its related partnerships or corporations, or the partners, agents or employees thereof, be liable to you or anyone else for any decision made or action taken in reliance on the information in any Publication, or for any loss of opportunity, loss of profit, loss of production, loss of business or indirect losses, special or similar damages of any kind, even if advised of the possibility of such losses or damages.